|
Authors | Species | Melatonin in vitro/in vivo | Patients number (tot) | Intervention/control number | Technique | Significant outcomes () |
|
Lord et al. 2013 [36] | Mouse | Adding M in oocyte culture medium | | | | (i) Increased number of oocytes that reached blastocyst stage |
|
Kang et al. 2009 [37] | Porcine | Adding M in oocyte culture medium | | | | (i) Increased mature oocyte |
|
Tamura et al. 2008 [32] | Human | Orally administered M (3 mg/day) | 115 | 56 versus 56 nontreated 1° cycle versus treated 2° cycle | IVF-ET | (i) Improved fertilization rate |
M (3 mg/day) versus Vit. E (600 mg/day) versus M + Vit. E (3 mg + 600 mg/day) | 18 | 59 versus 59 nontreated 1° cycle versus nontreated 2° cycle | (i) Reduced 8-OHdG in FF (ii) Increased in FF in treated patient. |
|
Kim et al. 2013 [33] | Human | Adding M in oocyte culture medium | 111 | 62/49 | IVM IVF-ET | (i) Increased mature oocyte (ii) Increased implantation |
|
Batioglu et al. 2012 [39] | Human | Orally administered M (3 mg/day) | 85 | 40/45 | IVF-ET | (i) Increased mature oocyte (ii) Increased good quality embryos |
|
Eryilmaz et al. 2011 [40] | Human | Orally administered M (3 mg/day) | 60 | 30/30 | IVF-ET | (i) Increased mature oocyte (ii) Increased good quality embryos |
|
Nishihara et al. 2014 [41] | Human | Orally administered M (3 mg/day) | 97 | 97/97 (control of itself) | IVF ICSI | (i) Improved fertilization with ICSI (ii) Improved fertilization in poor responder (iii) Improved good quality embryos |
|